Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092585 | 0.81 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL9726458 | 0.80 | ALDH1A1 (0.67) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL19998299 | 0.78 | ALDH1A1 (0.64) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL80183 | 0.78 | ALDH1A1 (0.64) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL103586 | 0.78 | ALDH1A1 (1.00) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL976845 | 0.76 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL783928 | 0.76 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL11652644 | 0.76 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA | |
| SCHEMBL320037 | 0.76 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA | |
| Hydrochloric Acid SCHEMBL8042412 | 0.76 | ALDH1A1 (0.61) | ALDH1A1FEN1HPGDNPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| EP-3179991-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | Acerta Pharma B.V. (NL) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| EP-2019671-B1 | INTERMEDIATES FOR THE PREPARATION OF BIVALENT SMAC MIMETICS | UNIV MICHIGAN (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2139490-B1 | DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8664212-B2 | Diazo bicyclic Smac mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-04 | — | — | US | disclosed |
| US-8557812-B2 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-15 | — | — | US | disclosed |
| US-5552400-A | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995033751-A1 | BICYCLING LACTAM INHIBITOR OF INTERLEUKIN-1-BETA CONVERTING ENZYME | SANOFI WINTHROP, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5262385-A | Pyrimidine ring containing | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0468766-A1 | Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor | Mitsubishi Chemical Corporation (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0379174-A2 | 2,3-Dihydro-3,3-dimethyl-5-trifluoromethanesulfonyloxybenzofurans, process for producing them and herbicides containing them | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885FEN1 3389/4885HPGD 4346/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885FEN1 3389/4885HPGD 4346/4885 |
| US-20180250298-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885FEN1 3389/4885HPGD 4346/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885FEN1 3389/4885HPGD 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.